» Authors » Michel Lecendreux

Michel Lecendreux

Explore the profile of Michel Lecendreux including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 100
Citations 3024
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Peter-Derex L, Fort E, Putois B, Martel N, Ricordeau F, Bastuji H, et al.
Sleep Med . 2025 Mar; 129:148-166. PMID: 40024108
Objectives: In this multi-center cross-sectional study, we compared substance use patterns (SUPs) between patients with narcolepsy type 1 (NT1) and controls, and investigated, among patients, factors associated with the consumption...
2.
Peter-Derex L, Fort E, Putois B, Martel N, Ricordeau F, Bastuji H, et al.
J Clin Sleep Med . 2025 Feb; PMID: 39943847
Study Objectives: This multi-center comparative cross-sectional study aimed to describe educational and occupational pathways, quantify effort/reward imbalance at work and identify factors associated with professional prognosis in patients with narcolepsy...
3.
Berthier J, Endomba F, Lecendreux M, Mauries S, Geoffroy P
Neuroscience . 2024 Dec; 567:67-76. PMID: 39631658
Background And Objectives: Attention deficit hyperactivity disorder (ADHD) is one of the most frequent and disabling neurodevelopmental disorders. Recent research on cerebral blood flow (CBF) has enhanced understanding of the...
4.
Ferrazzini L, Schmidt M, Zhang Z, Khatami R, Dauvilliers Y, Barateau L, et al.
J Sleep Res . 2024 Oct; :e14365. PMID: 39428908
The aim of the present study was to examine gender and age-specific effects on subjective daytime sleepiness (as measured by the Epworth Sleepiness Scale), body weight and eating behaviour in...
5.
Barateau L, Krache A, Da Costa A, Lecendreux M, Chenini S, Arlicot N, et al.
Neurol Neuroimmunol Neuroinflamm . 2024 Jun; 11(4):e200263. PMID: 38885456
Objectives: Kleine-Levin syndrome (KLS) is a rare recurrent hypersomnolence disorder associated with cognitive and behavioral disturbances, of unknown origin, but inflammatory mechanisms could be involved. We aimed to explore in...
6.
Barateau L, Krache A, Da Costa A, Lecendreux M, Debs R, Chenini S, et al.
Neurology . 2024 Apr; 102(10):e209326. PMID: 38669634
Background And Objectives: Narcolepsy type 1 (NT1) is due to the loss of hypothalamic neurons that produce orexin (ORX), by a suspected immune-mediated process. Rare postmortem studies are available and...
7.
Plazzi G, Pizza F, Lecendreux M, Gringras P, Barateau L, Bruni O, et al.
J Sleep Res . 2023 Dec; 33(4):e14055. PMID: 38050449
No abstract available.
8.
Dauvilliers Y, Lammers G, Lecendreux M, Maski K, Kansagra S, Black J, et al.
J Clin Sleep Med . 2023 Nov; 20(3):445-454. PMID: 37942930
Study Objectives: We examined body mass index (BMI) changes associated with sodium oxybate treatment (SXB) in pediatric patients with narcolepsy with cataplexy who participated in a double-blind, placebo-controlled, randomized withdrawal...
9.
Ollila H, Sharon E, Lin L, Sinnott-Armstrong N, Ambati A, Yogeshwar S, et al.
Nat Commun . 2023 May; 14(1):2709. PMID: 37188663
Narcolepsy type 1 (NT1) is caused by a loss of hypocretin/orexin transmission. Risk factors include pandemic 2009 H1N1 influenza A infection and immunization with Pandemrix®. Here, we dissect disease mechanisms...
10.
Dauvilliers Y, Lecendreux M, Lammers G, Franco P, Poluektov M, Causse C, et al.
Lancet Neurol . 2023 Mar; 22(4):303-311. PMID: 36931805
Background: Narcolepsy is a life-long disorder characterised by excessive daytime sleepiness and cataplexy, often arising in childhood or adolescence. Pitolisant, a selective histamine H3 receptor inverse agonist, has been approved...